Letter to the Editor

Liver injury with autoimmune features after vaccination against SARS-CoV-2: The verdict is still open

A R T I C L E   I N F O

Keywords
Autoimmune hepatitis
Drug induced liver injury
SARS-CoV-2 vaccine

Dear Editor,

We read with interest recent reports describing acute hepatic injury following vaccination against SARS-CoV-2 [1]. The clinical expression of the hepatic involvement ranges from mild hepatitis to acute liver failure requiring liver transplantation [2], and biochemical, serological and histological features are typical of autoimmune hepatitis (AIH). We herein describe suspected SARS-CoV-2 vaccine-related liver injury with autoimmune features occurring in three young patients, in whom other causes of acute hepatitis, such as hepatitis A, B, C, D, E, drug induced liver injury, alcohol, have been excluded after accurate clinical, biochemical, and virological assessment. Detailed liver biopsy findings for each case are presented in Table 1.

The first patient is a 30-years-old woman with Hashimoto thyroiditis and family history of autoimmune diseases (ADs) who received two doses of the Moderna vaccine in September and October 2021. In November 2021 she complained of asthenia, hyporexia, arthralgia and dark urine. Alanine transaminase (ALT) levels were 60-fold upper limit of normal (ULN), total bilirubin was 33.5 µmol/L, IgG was 1642 mg/dL and antinuclear antibodies (ANAs) tested positive at 1:640 titer with homogeneous pattern, while anti-smooth muscle antibody (ASMA), anti-SLA/LP, anti-LKM and anti-LC1 tested negative. A liver biopsy showed perportal lympho-plasmocytic infiltrate with interface hepatitis, without significant fibrosis (Table 1). The patient received high-dose N-acetylcysteine, while she refused steroid treatment. ALT levels decreased to normal in 8 weeks; one month later they were still moderately elevated (up to 3-fold), then normalized again spontaneously. The second patient is a 26-years-old male with vitiligo and pollen allergy, who has been taking maltodextrin and amino-acid supplements for several years. He performed routine blood tests on a regular basis and had his liver function consistently normal. He received two doses of the Moderna vaccine in June and July 2021, and in August he discovered altered ALT levels 1.9-fold ULN, progressively increasing up to a 10-fold peak in November, with IgG 1749 mg/dL, total bilirubin 15.4 µmol/L. ANAs were positive at 1:640 titer with homogeneous pattern, while ASMA, anti-SLA/LP and anti-LKM were negative. Liver biopsy showed mild portal lymphoplasmocytic infiltrate with mild-moderate interface hepatitis, without significant fibrosis (Table 1). HLA was A1, B8, DR3. Immunosuppressive treatment was declined, and transaminase levels remained altered (around 3-fold) in the following months. The third patient is a 21-years-old girl with no significant medical history. She came to our attention in November 2021 for persistent 2-fold ALT increase since March 2021 found on routine blood test, before the first vaccination cycle. In November ALT were 2-fold ULN, ASMA were positive at 1:320 titer, ANAs at 1:80 titer with homogeneous pattern, IgG were 1502 mg/dL, and liver biopsy showed perportal lympho-plasmocytic and lobular inflammatory infiltrate and focal piecemeal necrosis with moderate perportal fibrosis (Table 1). HLA was A1, B8, DR3. A diagnosis of genuine AIH was made, but therapy was declined due to patient hesitancy. In December, a few days after the booster dose (Moderna), she developed a hepatitis flare with ALT levels up to 12-fold ULN, so steroid therapy was initiated with rapid normalization of ALT. Retrospectively, she was noted to have a slight ALT increase (peak 4.7 x ULN) two weeks after the second dose of the Pfizer vaccine in May 2021, with subsequent return to a 2-fold ULN during following months.

AIH is a persistent, fluctuating inflammation of the liver observed in genetically predisposed subjects after exposure to an initiating, mostly unknown, factor [3]. Vaccines have been proposed as potential triggers [4,5]. The association of SARS-CoV-2 vaccination and AIH has been increasingly reported: a systematic review recently reported 32 patients [4,5]. The association of SARS-CoV-2 vaccination and AIH has been increasingly reported: a systematic review recently reported 32 patients in the period December 2019 – November 21 [1].

In Supplementary material we reviewed the available case reports of AIH like liver injury until June 2022. The search was performed using PubMed, entering as keywords “COVID vaccine”, “SARS-CoV-2 vaccine”, “Autoimmune hepatitis” and “Liver injury”, last access in June 2022.
were disease evolved to overt liver failure, of which two died and one course was favorable in almost all cases, even if in three reports (6%) the case leading to hepatitis relapse requiring oral steroids. The clinical previously altered ALT levels and liver fibrosis indicated a long-standing which was rapidly controlled with steroid treatment. In the latter case, after the Moderna booster a striking increase of ALT was observed, abnormal and fluctuating for the second one. For the third patient, and self-limiting for the first patient, less acute but persistently interesting, the kinetics of biochemical hepatic damage was quite process, pointing to pre-existing AIH. Of note, as well as this “genuine AIH”, even the first two patients had a preexistent AD, highlighting predisposition to AIH-like liver injury after vaccination. Efe et al. reported that 28% of the AIH-like-liver-injury patients had been diagnosed with other AD before liver injury onset, of which most common are autoimmune thyroiditis (14%), inflammatory bowel diseases (3%) and sarcoidosis (3%) [2]. The significant proportion of patients with other ADs developing AIH-like liver injury suggest genetic predisposition, such as impaired clearance of nucleic acids, TLR polymorphism, HLA haplotype [7]. Various authors propose that vaccination may not generate new ADs, but rather triggers long-lasting latent autoimmunity [6,7]. The strong inflammatory response induced by pattern recognition receptors could act like a relapse trigger of a latent AIH, as shown for other ADs reactivation after SARS-CoV-2 vaccination [8]: this mechanism has been postulated since the early presentation with detectable pathogenic autoantibodies [8]. Other proposed mechanisms are bystander activation and epitope spreading [6] as well as molecular mimicry [7]. Interestingly, some reports suggest the possibility of SARS-CoV-2 Spike protein expression within hepatocytes after vaccination [9] and the presence of an immune infiltrate characterized by activated cytotoxic CD8 T-cells with SARS-CoV-2 Spike-protein specificity [10].

Whether these cases represent genuine AIH triggered by vaccine or transient vaccine-induced liver injury is at present a matter of debate, which only a longer follow up could figure out: recurrent flares of ALT or prolonged immunosuppression, whereas spontaneous and complete biochemical and histological resolution will indicate vaccine-induced liver injury. Cases of genuine AIH reactivation after vaccination emphasizes the need for close follow-up after vaccination, particularly when the immunosuppressive treatment has not been introduced yet. As of today, we are unable to prove the direct role of vaccination in the induction of hepatic damage, but we cannot disprove it either. Rigorous population-based studies and active pharmacovigilance are urgently needed to assess beyond reasonable doubt incidence and clinical significance of such observations. Until then, the final verdict should remain open.
Financial support

The authors received no financial support to produce this manuscript.

Authors contributions

MF co-wrote the original manuscript and edited the final submission; ML assisted with conceptualization and edited the final submission; LM provided patient care, co-wrote the original manuscript and edited the final submission (Fig. 1).

Declaration of Competing Interest

No conflict of interest to declare

References


Marco Ferronato*, Marco Lenzi, Luigi Muratori
DIMEC Università di Bologna, IRCCS Policlinico di Sant’Orsola, Italy

* Corresponding author.
E-mail address: marco.ferronato@studio.unibo.it (M. Ferronato).